Detalles de la búsqueda
1.
Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy.
Anticancer Drugs
; 33(10): e842-e849, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36206101
2.
Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma.
Medicina (Kaunas)
; 58(7)2022 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35888627
3.
Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment.
Oncology
; 99(1): 32-40, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-32894845
4.
Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.
Anticancer Drugs
; 32(10): 1099-1104, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34232936
5.
Impact of tumor disappearance ratio on the prognosis of lung adenocarcinoma ≤2 cm in size: A retrospective cohort study.
J Formos Med Assoc
; 120(2): 874-882, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32891489
6.
Overexpression of Aurora-A bypasses cytokinesis through phosphorylation of suppressed in lung cancer.
Am J Physiol Cell Physiol
; 317(3): C600-C612, 2019 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31314582
7.
Transcriptional repression of Aurora-A gene by wild-type p53 through directly binding to its promoter with histone deacetylase 1 and mSin3a.
Int J Cancer
; 142(1): 92-108, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28884479
8.
EGFR mutation and lobar location of lung adenocarcinoma.
Carcinogenesis
; 37(2): 157-162, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26645716
9.
Mechanisms underlying lung resistance-related protein (LRP)-mediated doxorubicin resistance of non-small cell lung cancer cells.
Chin J Physiol
; 59(6): 331-347, 2016 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-27817195
10.
Interactions between household air pollution and GWAS-identified lung cancer susceptibility markers in the Female Lung Cancer Consortium in Asia (FLCCA).
Hum Genet
; 134(3): 333-41, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25566987
11.
Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib.
Ther Adv Med Oncol
; 16: 17588359231220606, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38188463
12.
Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study.
Lancet Respir Med
; 12(2): 141-152, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38042167
13.
EGFR exon 19 in-frame deletion and polymorphisms of DNA repair genes in never-smoking female lung adenocarcinoma patients.
Int J Cancer
; 132(2): 449-58, 2013 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22573488
14.
Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways.
Mol Carcinog
; 52(3): 183-94, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22086658
15.
Artificial Intelligence Assisted Computational Tomographic Detection of Lung Nodules for Prognostic Cancer Examination: A Large-Scale Clinical Trial.
Biomedicines
; 11(1)2023 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36672655
16.
Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma.
Front Oncol
; 13: 1096683, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36925928
17.
Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma.
Front Oncol
; 13: 1063695, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37007097
18.
Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer.
J Thorac Oncol
; 18(11): 1492-1503, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37414358
19.
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients.
Sci Rep
; 12(1): 9753, 2022 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35697720
20.
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.
Target Oncol
; 17(3): 295-306, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35460474